Serum-mediated leukemia cell destruction in AKR mice

Area of Science:

• Immunology
• Hematology
• Complement System Biology

Background:

• Spontaneous leukemia in AKR mice serves as a model for studying anti-leukemic therapies.
• The complement system is a critical component of innate immunity with diverse functions.
• Previous research has implicated serum factors in the control of certain cancers.

Purpose of the Study:

• To investigate the role of normal serum and its components in the destruction of spontaneous leukemia cells in AKR mice.
• To identify the specific complement component(s) responsible for the observed anti-leukemic activity.
• To explore the interaction between complement and other anti-leukemic agents like interferon and endotoxin.

Main Methods:

• Infusion of normal serum from various species into AKR mice with spontaneous leukemia.
• Assessment of leukemia cell destruction in response to different serum types, including those deficient in complement components.
• Inactivation of serum factors using heat treatment and cobra venom factor (CVF).
• Testing of individual complement factors to pinpoint the active component.

Main Results:

• Serum from mice with a complete complement system, as well as serum from guinea pigs, horses, and humans, induced leukemia cell destruction.
• Serum deficient in complement component 5 (C5) failed to produce leukemia cell destruction, indicating C5's critical role.
• The anti-leukemic factor in serum was heat-labile and inactivated by CVF, further supporting a complement-mediated mechanism.
• Complement component 5 (C5) was identified as the primary anti-leukemic factor in normal serum.
• Complement was also found to contribute to the anti-leukemic effects of interferon and endotoxin.

Conclusions:

• Complement component 5 (C5) in normal serum possesses significant anti-leukemic activity against spontaneous leukemia in AKR mice.
• The complement system, particularly C5, plays a vital role in mediating the destruction of leukemia cells.
• Complement activation is a key mechanism underlying the therapeutic effects of certain biological agents, including interferon and endotoxin, in leukemia treatment.